# An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives

> **NCT04476446** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag, S.A.** · enrollment: 41 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Esketamine

## Key facts

- **NCT ID:** NCT04476446
- **Lead sponsor:** Janssen-Cilag, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-08
- **Primary completion:** 2023-06-16
- **Final completion:** 2023-06-16
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04476446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04476446, "An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04476446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*